衆生藥業(002317.SZ):全資子公司獲得氯貝酸鋁化學原料藥上市申請批準通知書
格隆匯7月25日丨衆生藥業(002317.SZ)公佈,公司全資子公司廣東先強藥業有限公司於近日收到國家藥品監督管理局覈準簽發的原料藥氯貝酸鋁《化學原料藥上市申請批準通知書》。
氯貝酸鋁是氯貝丁酸衍生物類血脂調節藥,在胃中不分解,對胃無刺激,在腸道鹼性環境中分解爲氯貝丁酯而起作用。氯貝酸鋁通過降低極低密度脂蛋白的量,達到降血脂的目的。氯貝酸鋁作爲有效成分應用於脂降寧片(安絡寧片)、複方毛冬青氯貝酸鋁片、氯貝酸鋁片等產品中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.